PMV Pharmaceuticals
PMVP
69 hedge funds and large institutions have $45.8M invested in PMV Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
21% more capital inflows, than outflows
Capital inflows: $13.5M | Capital outflows: $11.2M
6% more funds holding
Funds holding: 65 → 69 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.02% less ownership
Funds ownership: 70.33% → 69.31% (-1%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eversept Partners
New York
|
+$2.99M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.37M |
| 3 |
Two Sigma Investments
New York
|
+$1.5M |
| 4 |
Morgan Stanley
New York
|
+$973K |
| 5 |
Longaeva Partners
Chicago,
Illinois
|
+$702K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$6.22M |
| 2 |
Tang Capital Management
San Diego,
California
|
-$884K |
| 3 |
Stonepine Capital Management
Bend,
Oregon
|
-$563K |
| 4 |
Jane Street
New York
|
-$476K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$438K |
PMVP Hedge Fund Activity: Q1 2026 in Review
69 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2026, worth a combined $45.8M — down 2% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PMVP positions and 10 closed out — a net gain of 5 holders — while 16 added to existing stakes and 20 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $2.99M. The largest seller was OrbiMed, exiting entirely with an estimated $6.22M sold.
- 69 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2026, up from 65 in Q4 2025.
- Funds reported $45.8M of PMV Pharmaceuticals stock for Q1 2026, down 2% quarter-over-quarter.
- 15 funds opened new PMV Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +5 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $2.99M added.
- The largest PMV Pharmaceuticals seller in Q1 2026 was OrbiMed, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2026.